Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INDP
Strong SellSinkerIndaptus Therapeutics, Inc. · Healthcare · United States · $152M · Avg Vol: $2M/d
10
StockRankGet insider-trade alerts
Q
27
V
23
M
35
P/E (TTM)
—
ROE
-318.0%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — |
| EPS | — | -0.11 | -0.12 | -0.15 | -0.35 | — | — |
| Shares | — | 133.2M | 133.2M | 133.2M | 133.2M | 0.0% | 133.2M |
| Debt | — | 80.5K | 0.2M | 84.2K | 0 | 2.3% | — |
| Equity | — | 24.6M | 12.1M | 3.9M | 3.2M | -49.6% | — |
| Op CF | — | -13.1M | -13.4M | -12.3M | -14.8M | — | -14.7M |
| Inv CF | 0.4M | -16.4M | 17.1M | 0 | — | — | — |
| Fin CF | — | 0 | 0 | 4.7M | 17.5M | — | — |
Loading 1Y...
PRICE (1Y)+14.3%
SMA 50SMA 200
Close
$2.08
RSI (14)
81.7
52W High
$8.57
From 52W High
0.2%
SCORE BREAKDOWN
Quality
27
ROIC
-552.8%0.9
ROE
-318.0%2.7
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-115.7%1.7
Piotroski
211.9
Int. Cover
—N/A
D/E Ratio
0.00x98.0
Current Ratio
19.48x95.8
Value
23
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
14.4x8.3
P/S
—N/A
Div Yield
—N/A
Momentum
35
52W High %
24%4.8
RS 6M
-2%63.0
SMA 50/200
0.82x18.9
EPS Rev 4W
0.0%34.5
EPS Rev 12W
—N/A
EPS Improve
+61%61.3
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$152M
P/E (Forward)
-0.9x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INDP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INDP | Indaptus Therapeutics, Inc.(you) | $152M | 10 | Strong Sell |
| CNTB | Connect Biopharma Holdings Limited | $140M | 10 | Strong Sell |
| UNCY | Unicycive Therapeutics, Inc. | $144M | 11 | Strong Sell |
| KPTI | Karyopharm Therapeutics Inc. | $168M | 11 | Strong Sell |
| TNYA | Tenaya Therapeutics, Inc. | $155M | 14 | Strong Sell |
| OTLK | Outlook Therapeutics, Inc. | $156M | 14 | Strong Sell |
| CNTN | Canton Strategic Holdings, Inc. | $177M | 9 | Strong Sell |
| LENZ | LENZ Therapeutics, Inc. | $161M | 14 | Strong Sell |
| HURA | TuHURA Biosciences, Inc. | $134M | 7 | Strong Sell |
| VANI | Vivani Medical, Inc. | $128M | 12 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%